160 related articles for article (PubMed ID: 31281064)
21. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.
Piulats JM; Vidal A; García-Rodríguez FJ; Muñoz C; Nadal M; Moutinho C; Martínez-Iniesta M; Mora J; Figueras A; Guinó E; Padullés L; Aytés À; Molleví DG; Puertas S; Martínez-Fernández C; Castillo W; Juliachs M; Moreno V; Muñoz P; Stefanovic M; Pujana MA; Condom E; Esteller M; Germà JR; Capella G; Farré L; Morales A; Viñals F; García-Del-Muro X; Cerón J; Villanueva A
Clin Cancer Res; 2018 Aug; 24(15):3755-3766. PubMed ID: 29618620
[No Abstract] [Full Text] [Related]
22. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-Based Chemotherapy for Testicular Germ Cell Tumors: Complication Rates of Peripheral versus Central Venous Administration.
Worst T; Sautter L; John A; Weiss C; Häcker A; Heinzelbecker J
Urol Int; 2016; 96(2):177-82. PubMed ID: 26681435
[TBL] [Abstract][Full Text] [Related]
24. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
26. Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens.
Sattar A; Masood M; Nisar H; Fatima I; Shahid AB
J Coll Physicians Surg Pak; 2018 Apr; 28(4):292-296. PubMed ID: 29615170
[TBL] [Abstract][Full Text] [Related]
27. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
28. Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: an unusual case report.
Azak A; Oksüzoğlu B; Deren T; Oneç BM; Zengin N
Anticancer Drugs; 2008 Jan; 19(1):97-8. PubMed ID: 18043135
[TBL] [Abstract][Full Text] [Related]
29. Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up?
Koc G; Divrik TR; Unlu N; Bulut V; Zorlu F
Int Urol Nephrol; 2011 Dec; 43(4):1095-100. PubMed ID: 21505757
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
31. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
32. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
[TBL] [Abstract][Full Text] [Related]
33. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-related Cerebral Infarction in Testicular Germ Cell Cancer: Short Report of Three Cases and P in testicular germ cell cancer: Short report of three cases and pathomechanism.
Lange J; Audebert HJ; Endres M; Rocco A
Clin Neurol Neurosurg; 2017 Jan; 152():76-77. PubMed ID: 27923208
[No Abstract] [Full Text] [Related]
35. Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer.
Dulz S; Asselborn NH; Dieckmann KP; Matthies C; Wagner W; Weidmann J; Seidel C; Oing C; Berger LA; Alsdorf W; Mankichian B; Meyer C; Vetterlein MW; Gild P; Ludwig TA; Soave A; Schriefer P; Becker A; Ahyai SA; Oechsle K; Bokemeyer C; Wagenfeld L; Fisch M; Hartmann M; Chun FK; Kluth LA
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1319-1325. PubMed ID: 28281024
[TBL] [Abstract][Full Text] [Related]
36. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.
Pectasides D; Pectasides E; Papaxoinis G; Skondra M; Gerostathou M; Karageorgopoulou S; Kamposioras C; Tountas N; Koumarianou A; Psyrri A; Macheras A; Economopoulos T
J Androl; 2009; 30(3):280-6. PubMed ID: 19136393
[TBL] [Abstract][Full Text] [Related]
37. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients.
Sestakova Z; Kalavska K; Smolkova B; Miskovska V; Rejlekova K; Sycova-Mila Z; Palacka P; Obertova J; Holickova A; Hurbanova L; Jurkovicova D; Roska J; Goffa E; Svetlovska D; Chovanec M; Mardiak J; Mego M; Chovanec M
Mutat Res Genet Toxicol Environ Mutagen; 2020; 854-855():503200. PubMed ID: 32660824
[TBL] [Abstract][Full Text] [Related]
38. Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells.
Steinemann G; Dittmer A; Kuzyniak W; Hoffmann B; Schrader M; Schobert R; Biersack B; Nitzsche B; Höpfner M
Mol Cancer Ther; 2017 Nov; 16(11):2364-2374. PubMed ID: 28838999
[TBL] [Abstract][Full Text] [Related]
39. Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer.
Heidegger I; Porres D; Veek N; Heidenreich A; Pfister D
Urol Int; 2017; 99(1):104-109. PubMed ID: 28514776
[TBL] [Abstract][Full Text] [Related]
40. Testis-expressed gene 11 inhibits cisplatin-induced DNA damage and contributes to chemoresistance in testicular germ cell tumor.
Kitayama S; Ikeda K; Sato W; Takeshita H; Kawakami S; Inoue S; Horie K
Sci Rep; 2022 Nov; 12(1):18423. PubMed ID: 36319719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
